IMMUNE CHECKPOINT INHIBITORS
Clinical trials for IMMUNE CHECKPOINT INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITORS trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may let some breast cancer patients skip harsh chemo
Disease control Not yet recruitingThis study tests a new drug (QL1706) combined with chemotherapy before surgery in 40 people with early triple-negative breast cancer. The goal is to see if some patients can avoid a type of chemo called anthracyclines, which can harm the heart. After four cycles of treatment, tho…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 06:22 UTC
-
New triple therapy targets hard-to-treat bile duct cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) in 65 adults with advanced HER2-positive bile duct cancer that cannot be removed by surgery. The goal is to see how well the treatment shrinks tumors and how safe it is. Participan…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 12, 2026 13:39 UTC